Obtained marketing approval for Efmenoc Capsules 100 mg
First written in FY2021. 6 of 8 entries say "Restated". Latest entry: FY2023-Q3.
No other company in this theme has enough history to compare yet.
- FY2023-Q3RestatedAnnual report
「In this area, the company offers Efmeno Capsules 100mg, a natural progesterone formulation indicated for the suppression of endometrial hyperplasia when an estrogen preparation is administered for menopausal disorders and ovarian deficiency symptoms in the women's healthcare field (generic name: progesterone)」
Continues to identify Efmeno Capsules 100mg as a priority sales product in the women's healthcare field following approval and the start of sales. - FY2023-Q2RestatedAnnual report
「In this area, the company offers Efmeno Capsules 100mg, a natural progesterone formulation indicated for the suppression of endometrial hyperplasia when an estrogen preparation is administered for menopausal disorders and ovarian deficiency symptoms in the women's healthcare field (generic name: progesterone)」
Continues to identify Efmeno Capsules 100mg as a priority sales product in the women's healthcare field following approval and the start of sales. - FY2023-Q1RestatedAnnual report
「In this area, the company offers Efmeno Capsules 100mg, a natural progesterone formulation indicated for the suppression of endometrial hyperplasia when an estrogen preparation is administered for menopausal disorders and ovarian deficiency symptoms in the women's healthcare field (generic name: progesterone)」
Continues to identify Efmeno Capsules 100mg as a priority sales product in the women's healthcare field, based on the approval obtained in September 2021 and the start of sales in November of the same year. - FY2022RestatedAnnual report
「On 27 September 2021, we obtained Japan’s first manufacturing and marketing approval for Femeno capsules 100 mg, a natural progesterone product indicated for suppressing the onset of endometrial hyperplasia when estrogen is administered for menopausal disorders and ovarian loss symptoms, and commenced sales in November 2021.」
Continues to disclose the approval obtained for Efmeno Capsules 100mg in September 2021 and the start of sales in November of the same year. - FY2022-Q3RestatedAnnual report
「On 27 September 2021, we obtained Japan’s first manufacturing and marketing approval for Femeno capsules 100 mg, a natural progesterone product indicated for suppressing the onset of endometrial hyperplasia when estrogen is administered for menopausal disorders and ovarian loss symptoms, and commenced sales in November 2021.」
Continues to disclose the approval obtained for Efmeno Capsules 100mg in September 2021 and the start of sales in November of the same year. - FY2022-Q2RestatedAnnual report
「On 27 September 2021, we obtained Japan’s first manufacturing and marketing approval for Femeno capsules 100 mg, a natural progesterone product indicated for suppressing the onset of endometrial hyperplasia when estrogen is administered for menopausal disorders and ovarian loss symptoms, and commenced sales in November 2021.」
Continues to disclose the approval obtained for Efmeno Capsules 100mg in September 2021 and the start of sales in November of the same year. - FY2022-Q1AdvancedAnnual report
「On 27 September 2021, we obtained Japan’s first manufacturing and marketing approval for Femeno capsules 100 mg, a natural progesterone product indicated for suppressing the onset of endometrial hyperplasia when estrogen is administered for menopausal disorders and ovarian loss symptoms, and commenced sales in November 2021.」
States that sales of Efmeno Capsules 100mg began in November 2021, following the approval to manufacture and market the product disclosed in FY2021. - FY2021First statedAnnual report
「On 27 September 2021, we obtained Japan’s first manufacturing and marketing approval for Femeno capsules 100 mg, a natural progesterone product indicated for suppressing the onset of endometrial hyperplasia when estrogen is administered for menopausal disorders and ovarian loss symptoms.」
For the first time, records as an independent product development theme that domestic approval to manufacture and market Efmeno Capsules 100mg was obtained on 27 September 2021.